otezla-header-logo
  • GET STARTED
  • DISEASE AREAS
    • PSORIASIS
      • ACTUAL PATIENT RESULTS
      • EFFICACY PROFILE
      • SAFETY PROFILE
      • OUR EXPERIENCE
    • PSORIATIC ARTHRITIS
      • EFFICACY PROFILE
      • SAFETY PROFILE
      • OUR EXPERIENCE
    • NEW: BEHÇET’S DISEASE
      • EFFICACY PROFILE
      • SAFETY PROFILE
  • PHARMACOLOGY
  • ez Start PSP
  • SAFETY INFORMATION
  • CONTACT US
  • EN FR
  • MY PROFILE
  • LOG OUT

OTEZLA® is available on the RxHelpTM ONE program. The program covers up to the difference in cost between OTEZLA® and its generic alternative(s)*

* Available in select provinces only. Refers to drug acquisition cost and reasonable markup. Dispensing fees not covered. Program can end at the manufacturer’s discretion.

Enter site to learn more
  • BEHÇET’S DISEASE
  • EFFICACY PROFILE
  • SAFETY PROFILE
1st-only

OTEZLA is indicated for the treatment of adult
patients with oral ulcers associated with Behçet’s
disease who are candidates for systemic therapy1

patient-support-program-logo.svg

Contact the ez Start Patient Support Program:


1-844-ez-Start (1-844-397-8278)
Monday–Friday, 8:00 AM–8:00 PM ET
  • Privacy Policy
  • Terms of use
  • Cookie Settings
amgen-logo

OTEZLA® is a registered trademark of Amgen GmbH.

ez Start™ is a trademark owned or licensed by Amgen Inc.,
its subsidiaries or affiliates.

© 2025 Amgen Canada Inc. All rights reserved.

innovative-paab

CAN-407-1122-80010-E